Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)’s share price shot up 2% during trading on Thursday . The company traded as high as $1.52 and last traded at $1.47. 198,626 shares traded hands during trading, a decline of 6% from the average session volume of 210,388 shares. The stock had previously closed at $1.50.

A number of research firms recently commented on CATB. Wedbush reiterated an “ourperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a report on Monday, May 15th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $9.00 price target (down previously from $11.00) on shares of Catabasis Pharmaceuticals in a report on Monday, May 15th. Zacks Investment Research cut Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 19th. Finally, HC Wainwright lifted their price target on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Monday, August 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $4.50.

The stock has a 50 day moving average price of $1.26 and a 200 day moving average price of $1.35. The stock’s market capitalization is $32.60 million.

Catabasis Pharmaceuticals (NASDAQ:CATB) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.08. On average, equities analysts expect that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. grew its position in shares of Catabasis Pharmaceuticals by 33.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 30,000 shares during the period. Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals during the 1st quarter valued at approximately $106,000. Finally, Virtu KCG Holdings LLC bought a new position in shares of Catabasis Pharmaceuticals during the 2nd quarter valued at approximately $271,000. 32.90% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Catabasis Pharmaceuticals, Inc. (CATB) Shares Up -2%” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/07/catabasis-pharmaceuticals-inc-catb-shares-up-2.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.